Results:
Twenty-two patients developed IRAF (33%). Age at initiation of
ibrutinib was significantly associated with IRAF (65.1 years vs. 74.1
years, p = 0.002). Mean ibrutinib dose was lower among patients who
developed IRAF (388.2 ± 121.7 vs. 448.6 ± 88.4, p = 0.025). E/e’ was
significantly higher among patients who developed IRAF (11.5 vs. 9.3, p
= 0.04). PALS was significantly lower in patients who developed AF
(30.3% vs. 36.3%, p = 0.01). On multivariate regression analysis, age,
PALS and PACS were significantly associated with IRAF. On multivariate
regression analysis, only PACS remained significantly associated with
IRAF while accounting for age.